228 filings
Page 3 of 12
8-K
xvq1kmcmg02veuib0
12 Feb 21
Entry into a Material Definitive Agreement
8:00am
8-K
fnmmsf87bq b6d6q
14 Jan 21
Other Events
8:13am
8-K
htxuy yb74s
18 Dec 20
Entry into a Material Definitive Agreement
4:23pm
8-K
9vezjr5e90omxd1
11 Dec 20
Lexicon Announces Offering of Common Stock
5:28pm
8-K
f85o71kkkymmjw
11 Dec 20
Lexicon Pharmaceuticals Receives Fast Track Designation from the Fda for LX9211 for Diabetic Peripheral Neuropathic Pain
7:43am
8-K
lwza4
17 Nov 20
Results from Soloist and Scored Outcomes Studies
7:22am
8-K
p9ripih7ma
29 Oct 20
Lexicon Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical Update
7:02am
8-K
ged4qac
22 Oct 20
Entry into a Material Definitive Agreement
7:12am
8-K
uiu5ask
29 Sep 20
Unregistered Sales of Equity Securities
7:14am
8-K
lywzswbv uq4vdj
24 Sep 20
Unregistered Sales of Equity Securities
7:12am
8-K
0h0q2ec
11 Sep 20
Lexicon Pharmaceuticals Completes the Sale of Xermelo to
4:11pm
8-K
mbtnv9tewr38
8 Sep 20
Termination of a Material Definitive Agreement
5:02pm
8-K
9t3dtt5l wvilo
4 Aug 20
Cost Associated with Exit or Disposal Activities
12:00am
8-K
v42k4cubdzgx0
30 Jul 20
Lexicon Pharmaceuticals Enters into Agreement
7:18am
8-K
m1xw rgozb9jrpgxm1g
30 Jul 20
Lexicon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides a Business Update
7:04am
8-K
9m2w5avy3ns5y
15 Jul 20
Entry into a Material Definitive Agreement
5:06pm
8-K
j9f4y520hhsx8de
29 May 20
Termination of a Material Definitive Agreement
4:33pm
8-K
si07 apgbdb0l23bzwe
27 Apr 20
Entry into a Material Definitive Agreement
4:03pm
8-K
agq s0j6hs19l
27 Apr 20
Lexicon Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides a Business Update
7:04am
8-K
yz2bf8 bxrni3
12 Mar 20
Lexicon Pharmaceuticals Reports Fourth Quarter and Full-year 2019 Financial Results and Provides a Business Update
7:04am